Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
13%(1 trials)

Phase Distribution

Ph phase_2
4
50%
Ph phase_4
4
50%

Phase Distribution

0

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
4(50.0%)
Phase 4Post-market surveillance
4(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (50.0%)
Phase 44 (50.0%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_4

Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy

NCT01120795
completedphase_2

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

NCT00606086
completedphase_2

Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients

NCT01055821
completedphase_4

Improving Hepatitis C Treatment in Injection Drug Users

NCT00148031
completedphase_2

A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)

NCT00328549
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01120795Phase 4

Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy

Completed
NCT00606086Phase 2

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Completed
NCT01055821Phase 2

Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients

Completed
NCT00148031Phase 4

Improving Hepatitis C Treatment in Injection Drug Users

Completed
NCT00328549Phase 2

A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)

Completed
NCT00315432Phase 2

NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus Coinfection

Completed
NCT00575224Phase 4

Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9

Completed
NCT00383864Phase 4

Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8